Benzinga · Oct 19, 2026
BTIG Reiterates Buy on Bicara Therapeutics, Maintains $39 Price Target
BTIG analyst Jeet Mukherjee reiterates Bicara Therapeutics (NASDAQ:BCAX) with a Buy and maintains $39 price target.
BC
NASDAQ · BCAX
Bicara Therapeutics Inc. Common Stock
Healthcare · Biotechnology
$17.07
Down-$0.54 (-3.07%)
Updated Oct 25, 2026, 1:06 AM
SID Score
4.1/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.03B
- P/E ratio
- -10.02
- Dividend yield
- 0.00%
- 52-week range
- $13.70 – $30.99
- Volume
- 716.05K
- Avg. volume
- 676.71K
Price performance · BCAX
BCAX price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 23, 2026
BCAX closed at $17.07 after 20 trading sessions, down 9.20% for the selected period.
- Last close
- $17.07
- Period change
- -9.20%
- Period low
- $16.42
- Period high
- $18.80
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 23, 2026 | $17.53 | $17.85 | $16.98 | $17.07 | 716.05K |
| Oct 22, 2026 | $17.92 | $18.07 | $17.15 | $17.61 | 816.94K |
| Oct 21, 2026 | $18.31 | $18.78 | $17.90 | $17.91 | 656.72K |
| Oct 20, 2026 | $17.79 | $18.645 | $17.31 | $18.35 | 493.42K |
| Oct 19, 2026 | $16.92 | $17.60 | $16.60 | $17.47 | 865.42K |
| Oct 16, 2026 | $17.60 | $17.78 | $16.69 | $16.78 | 820.02K |
| Oct 15, 2026 | $17.51 | $17.95 | $17.25 | $17.62 | 662.06K |
| Oct 14, 2026 | $17.23 | $17.68 | $17.11 | $17.34 | 1.43M |
| Oct 13, 2026 | $17.29 | $17.61 | $17.01 | $17.34 | 1.27M |
| Oct 12, 2026 | $17.46 | $17.99 | $17.11 | $17.33 | 659.11K |
| Oct 9, 2026 | $17.19 | $17.82 | $16.88 | $17.50 | 715.97K |
| Oct 8, 2026 | $16.32 | $17.33 | $15.85 | $17.26 | 1.25M |
| Oct 7, 2026 | $16.44 | $17.11 | $16.2464 | $16.42 | 915.6K |
| Oct 6, 2026 | $17.43 | $17.52 | $16.31 | $16.56 | 981.2K |
| Oct 5, 2026 | $17.63 | $19.12 | $17.13 | $17.29 | 640.75K |
| Oct 2, 2026 | $18.50 | $18.9575 | $17.56 | $17.63 | 763.07K |
| Oct 1, 2026 | $18.61 | $19.23 | $18.12 | $18.20 | 698.05K |
| Sep 30, 2026 | $18.71 | $18.95 | $18.385 | $18.61 | 905.37K |
| Sep 29, 2026 | $18.88 | $19.39 | $18.51 | $18.56 | 599.78K |
| Sep 28, 2026 | $19.21 | $19.26 | $18.59 | $18.80 | 775.26K |
Latest BCAX news
The latest Smart Investors Daily articles mentioning BCAX.
Stock researchCompany · Overview
Company
Market Activity
Research & News
BCAX research
Overview
Company profile and research snapshot.
Company profile
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $40.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 19, 2026 | BTIG | Buy | — |
| Aug 19, 2026 | BMO Capital | Outperform | — |
| Aug 12, 2026 | Morgan Stanley | Overweight | — |
| Aug 12, 2026 | Wedbush | Outperform | — |
| Aug 12, 2026 | Goldman Sachs | Neutral | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 10, 2026
Bicara Therapeutics (BCAX) Stock May Look Overvalued On Book Value
Bicara Therapeutics has seen its share price under pressure recently, which puts fresh focus on whether the current market value lines up with what its balance sheet actually supports. With a book value driven by early stage biotech assets rather than mature cash flows, the question is how much of today's price is backed by what is already on the books versus what investors expect for the future. The stock has fallen 26.0% over the past month, which raises the question of how much of the...
Yahoo · Oct 5, 2026
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced it awarded inducement grants on October 1, 2026 to two new employees as a material inducement to employment under Bicara’s 2026 Inducement Plan. The employees received, in the aggregate, non-qualified stock options to purchase 207,150 shares of Bicara’s common stock,
Yahoo · Sep 3, 2026
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced it awarded inducement grants on September 1, 2026 to two new employees as a material inducement to employment under Bicara’s 2026 Inducement Plan. The employees received, in the aggregate, non-qualified stock options to purchase 380,575 shares of Bicara’s common sto
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
